What is HC Wainwright’s Estimate for APLS FY2030 Earnings?

Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) – Research analysts at HC Wainwright issued their FY2030 earnings per share estimates for Apellis Pharmaceuticals in a note issued to investors on Wednesday, February 25th. HC Wainwright analyst D. Tsao forecasts that the company will post earnings per share of $1.97 for the year. HC Wainwright currently has a “Buy” rating and a $48.00 price target on the stock. The consensus estimate for Apellis Pharmaceuticals’ current full-year earnings is ($1.70) per share.

Apellis Pharmaceuticals (NASDAQ:APLS) last issued its quarterly earnings results on Tuesday, February 24th. The company reported $0.47 earnings per share for the quarter, topping the consensus estimate of ($0.39) by $0.86. Apellis Pharmaceuticals had a net margin of 2.23% and a return on equity of 8.20%. The company had revenue of $199.91 million during the quarter, compared to analysts’ expectations of $199.28 million. During the same period last year, the business earned ($0.29) EPS. The business’s quarterly revenue was down 5.9% on a year-over-year basis.

Other equities research analysts have also recently issued reports about the stock. Needham & Company LLC cut their price target on shares of Apellis Pharmaceuticals from $29.00 to $28.00 and set a “buy” rating on the stock in a research report on Tuesday, January 13th. Citigroup lowered their target price on shares of Apellis Pharmaceuticals from $45.00 to $44.00 and set a “buy” rating on the stock in a report on Wednesday. Robert W. Baird increased their price target on shares of Apellis Pharmaceuticals from $50.00 to $52.00 and gave the company an “outperform” rating in a research note on Friday, October 31st. TD Cowen dropped their target price on shares of Apellis Pharmaceuticals from $50.00 to $45.00 and set a “buy” rating on the stock in a report on Friday, October 31st. Finally, Cantor Fitzgerald reduced their target price on Apellis Pharmaceuticals from $39.00 to $35.00 and set an “overweight” rating for the company in a research note on Tuesday, January 13th. Twelve equities research analysts have rated the stock with a Buy rating, seven have assigned a Hold rating and two have issued a Sell rating to the company. Based on data from MarketBeat.com, Apellis Pharmaceuticals presently has a consensus rating of “Hold” and an average price target of $32.61.

Apellis Pharmaceuticals Stock Performance

Shares of APLS stock opened at $21.64 on Thursday. Apellis Pharmaceuticals has a 12 month low of $16.10 and a 12 month high of $30.48. The company’s fifty day simple moving average is $23.07 and its 200-day simple moving average is $23.81. The firm has a market cap of $2.77 billion, a PE ratio of 166.47 and a beta of 0.26. The company has a quick ratio of 3.10, a current ratio of 3.14 and a debt-to-equity ratio of 0.98.

Institutional Trading of Apellis Pharmaceuticals

A number of institutional investors and hedge funds have recently made changes to their positions in APLS. Vanguard Group Inc. increased its stake in Apellis Pharmaceuticals by 6.9% in the fourth quarter. Vanguard Group Inc. now owns 10,674,865 shares of the company’s stock valued at $268,153,000 after acquiring an additional 687,471 shares during the last quarter. Deep Track Capital LP boosted its holdings in shares of Apellis Pharmaceuticals by 14.3% in the 3rd quarter. Deep Track Capital LP now owns 8,000,382 shares of the company’s stock valued at $181,049,000 after purchasing an additional 1,000,382 shares in the last quarter. RTW Investments LP acquired a new stake in shares of Apellis Pharmaceuticals in the 4th quarter valued at $192,589,000. AQR Capital Management LLC increased its stake in shares of Apellis Pharmaceuticals by 46.6% in the 2nd quarter. AQR Capital Management LLC now owns 5,976,414 shares of the company’s stock valued at $103,452,000 after purchasing an additional 1,898,995 shares during the last quarter. Finally, State Street Corp raised its holdings in shares of Apellis Pharmaceuticals by 14.3% during the 4th quarter. State Street Corp now owns 4,613,446 shares of the company’s stock worth $115,890,000 after buying an additional 575,802 shares in the last quarter. Institutional investors own 96.29% of the company’s stock.

Insider Buying and Selling at Apellis Pharmaceuticals

In other Apellis Pharmaceuticals news, CEO Cedric Francois sold 27,192 shares of Apellis Pharmaceuticals stock in a transaction dated Thursday, January 22nd. The shares were sold at an average price of $21.77, for a total value of $591,969.84. Following the completion of the sale, the chief executive officer owned 286,045 shares in the company, valued at $6,227,199.65. The trade was a 8.68% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, General Counsel David O. Watson sold 7,832 shares of the stock in a transaction that occurred on Thursday, January 22nd. The stock was sold at an average price of $21.77, for a total transaction of $170,502.64. Following the transaction, the general counsel owned 88,531 shares in the company, valued at approximately $1,927,319.87. The trade was a 8.13% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold 120,537 shares of company stock valued at $2,608,532 in the last quarter. Company insiders own 6.50% of the company’s stock.

Trending Headlines about Apellis Pharmaceuticals

Here are the key news stories impacting Apellis Pharmaceuticals this week:

• Positive Sentiment: HC Wainwright raised its long‑range outlook (FY2030 EPS to $1.97), reiterated a “Buy” and lifted its price target to $48 — a strongly bullish signal that likely supported buying interest this session. HC Wainwright raises target to $48
• Neutral Sentiment: Citigroup trimmed its target from $45 to $44 but kept a “Buy” rating — a modestly cautious move that is unlikely to materially change conviction among bullish investors. Citigroup price target update
• Neutral Sentiment: Earnings/transcript sources for the Feb. 24 Q4 call are circulating (full transcript available) — the call contains detail investors will parse for guidance and product trends; headlines are mixed across outlets. Earnings call transcript (Yahoo) Earnings call transcript (InsiderMonkey)
• Neutral Sentiment: Short‑interest data released shows “0 shares” and NaN changes — this is almost certainly a reporting or processing error and should not be treated as a genuine change in borrow/short pressure.
• Negative Sentiment: Royal Bank of Canada cut its target to $21 and moved to “Sector Perform,” which signals lower near‑term expectations and adds selling pressure for more cautious holders. RBC target cut Coverage note
• Negative Sentiment: Wedbush lowered its target to $18 and moved to “Neutral,” another sign of reduced analyst conviction that could weigh on the stock if follow‑through selling occurs. Wedbush target cut Coverage note
• Negative Sentiment: Zacks flagged a wider‑than‑expected Q4 loss and an 8% slip in Syfovre sales (though total revenue beat estimates and Empaveli grew on a new indication) — mixed results that may keep some investors cautious until product trends clarify. Zacks earnings summary

Apellis Pharmaceuticals Company Profile

Apellis Pharmaceuticals, Inc, traded as NASDAQ:APLS, is a clinical-stage biopharmaceutical company focused on the development of novel therapies targeting the complement cascade for the treatment of rare and debilitating diseases. The company’s research and development efforts center on modulating complement proteins to address a range of ophthalmologic, hematologic and renal conditions. Apellis leverages its proprietary compstatin technology platform to design targeted inhibitors intended to improve patient outcomes and quality of life.

The company’s lead marketed product, Syfovre (pegcetacoplan), is an intravitreal complement C3 inhibitor approved for geographic atrophy secondary to age-related macular degeneration, with ongoing investigations in other retinal disorders.